Cargando…

Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon

BACKGROUND: The cause and clinical significance of the transient decrease in platelet (PLT) count observed in relapsing remitting multiple sclerosis (RRMS) during alemtuzumab administration remain undefined. The aim of this study was to analyse the kinetics and clinical relevance of early onset thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Puthenparampil, Marco, Rinaldi, Francesca, Federle, Lisa, Cazzola, Chiara, Perini, Paola, Gallo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784536/
https://www.ncbi.nlm.nih.gov/pubmed/29399047
http://dx.doi.org/10.1177/1756285617741056
_version_ 1783295461908545536
author Puthenparampil, Marco
Rinaldi, Francesca
Federle, Lisa
Cazzola, Chiara
Perini, Paola
Gallo, Paolo
author_facet Puthenparampil, Marco
Rinaldi, Francesca
Federle, Lisa
Cazzola, Chiara
Perini, Paola
Gallo, Paolo
author_sort Puthenparampil, Marco
collection PubMed
description BACKGROUND: The cause and clinical significance of the transient decrease in platelet (PLT) count observed in relapsing remitting multiple sclerosis (RRMS) during alemtuzumab administration remain undefined. The aim of this study was to analyse the kinetics and clinical relevance of early onset thrombocytopaenia in alemtuzumab-treated RRMS. METHODS: A total of 26 patients with RRMS were included in a longitudinal study. Blood samples were collected immediately before the first alemtuzumab infusion (D0), and after 3 days (D3), 28 days (D28) and 49 days (D49). PLT, red blood cell (RC), leucocyte and lymphocyte counts, haemoglobin (Hb) concentration and haematocrit (Htc) were measured. Patients with MS were clinically evaluated every day of drug infusion and then at D28 and D49 to verify the presence of signs or symptoms suggestive of thrombocytopaenia. RESULTS: PLT number significantly decreased at D3 (p < 0.005) and was associated with a decrease in RC count (r: 0.53, p < 0.01), Hb (r: 0.42, p = 0.05) and Htc (r: 0.53, p < 0.01). A progressive reversion of PLT number to normal values was observed at D28 and D49. A mild thrombocytopaenia was observed in 12 patients (46.2%), 8 of which (66.6%) had PLT nadir values at D3, and 4 (33.3%) at D28. No sign or symptom suggestive of thrombocytopaenia was observed. A strong correlation between pretreatment and nadir PTL counts (r: 0.59, p < 0.005) was observed; indeed, mild thrombocytopaenia was observed more frequently in these patients with a baseline PTL count lower than 230 × 10(9)/L (83.3% versus 42.9%, p < 0.05). CONCLUSIONS: The early PLT decrease in alemtuzumab-treated patients is transient, mild, not associated with clinically relevant events and is probably related to the cytokine-released syndrome. Notwithstanding this, our findings suggest the opportunity for PLT monitoring during infusion and in the following 2 months, since a decrease in PLT count may occur.
format Online
Article
Text
id pubmed-5784536
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-57845362018-02-02 Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon Puthenparampil, Marco Rinaldi, Francesca Federle, Lisa Cazzola, Chiara Perini, Paola Gallo, Paolo Ther Adv Neurol Disord Original Research BACKGROUND: The cause and clinical significance of the transient decrease in platelet (PLT) count observed in relapsing remitting multiple sclerosis (RRMS) during alemtuzumab administration remain undefined. The aim of this study was to analyse the kinetics and clinical relevance of early onset thrombocytopaenia in alemtuzumab-treated RRMS. METHODS: A total of 26 patients with RRMS were included in a longitudinal study. Blood samples were collected immediately before the first alemtuzumab infusion (D0), and after 3 days (D3), 28 days (D28) and 49 days (D49). PLT, red blood cell (RC), leucocyte and lymphocyte counts, haemoglobin (Hb) concentration and haematocrit (Htc) were measured. Patients with MS were clinically evaluated every day of drug infusion and then at D28 and D49 to verify the presence of signs or symptoms suggestive of thrombocytopaenia. RESULTS: PLT number significantly decreased at D3 (p < 0.005) and was associated with a decrease in RC count (r: 0.53, p < 0.01), Hb (r: 0.42, p = 0.05) and Htc (r: 0.53, p < 0.01). A progressive reversion of PLT number to normal values was observed at D28 and D49. A mild thrombocytopaenia was observed in 12 patients (46.2%), 8 of which (66.6%) had PLT nadir values at D3, and 4 (33.3%) at D28. No sign or symptom suggestive of thrombocytopaenia was observed. A strong correlation between pretreatment and nadir PTL counts (r: 0.59, p < 0.005) was observed; indeed, mild thrombocytopaenia was observed more frequently in these patients with a baseline PTL count lower than 230 × 10(9)/L (83.3% versus 42.9%, p < 0.05). CONCLUSIONS: The early PLT decrease in alemtuzumab-treated patients is transient, mild, not associated with clinically relevant events and is probably related to the cytokine-released syndrome. Notwithstanding this, our findings suggest the opportunity for PLT monitoring during infusion and in the following 2 months, since a decrease in PLT count may occur. SAGE Publications 2017-11-29 /pmc/articles/PMC5784536/ /pubmed/29399047 http://dx.doi.org/10.1177/1756285617741056 Text en © The Author(s), 2017 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Puthenparampil, Marco
Rinaldi, Francesca
Federle, Lisa
Cazzola, Chiara
Perini, Paola
Gallo, Paolo
Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
title Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
title_full Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
title_fullStr Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
title_full_unstemmed Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
title_short Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
title_sort decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784536/
https://www.ncbi.nlm.nih.gov/pubmed/29399047
http://dx.doi.org/10.1177/1756285617741056
work_keys_str_mv AT puthenparampilmarco decreasedplateletnumberinmultiplesclerosisduringalemtuzumabinfusionacommontransientandclinicallysilentphenomenon
AT rinaldifrancesca decreasedplateletnumberinmultiplesclerosisduringalemtuzumabinfusionacommontransientandclinicallysilentphenomenon
AT federlelisa decreasedplateletnumberinmultiplesclerosisduringalemtuzumabinfusionacommontransientandclinicallysilentphenomenon
AT cazzolachiara decreasedplateletnumberinmultiplesclerosisduringalemtuzumabinfusionacommontransientandclinicallysilentphenomenon
AT perinipaola decreasedplateletnumberinmultiplesclerosisduringalemtuzumabinfusionacommontransientandclinicallysilentphenomenon
AT gallopaolo decreasedplateletnumberinmultiplesclerosisduringalemtuzumabinfusionacommontransientandclinicallysilentphenomenon